Humoral and cellular immunogenicity of a fourth dose BNT162b2 in children with chronic kidney diseases.

ABSTRACT:

Background

Children with chronic kidney disease (CKD) are at risk of severe complications after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and are recommended to receive vaccine boosters. Although coronavirus disease 2019 (COVID-19) boosters are effective in providing immune responses among healthy children, data on the use of a fourth dose among children with CKD are limited.

Methods

We prospectively investigated the immunogenicity and safety of a fourth dose of BNT162b2 in children with CKD. Dosages were 0.1 mL and 0.3 mL for children aged 5-11 years and 11-18 years, respectively. Humoral and cellular immunogenicity was assessed at pre-dose 4, and at 1 and 6 months post-dose 4.

Results

Twenty-one children, with a median age of 14.0 years,

SUBMITTER: Chan JCH 

PROVIDER: S-EPMC11926591 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature